Pacific Biosciences of California PACB Convertible Debt (Non-Current)
Convertible Debt (Non-Current) at other companies
Other financials
Where this comes from
Reported directly by Pacific Biosciences of California in its filing.
Tagged under the XBRL concept us-gaap:ConvertibleLongTermNotesPayable.
The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacific Biosciences of California's convertible debt (non-current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacific Biosciences of California's convertible debt (non-current)?
- Pacific Biosciences of California (PACB) reported convertible debt (non-current) of $644.11M in Q1 2026.
- How has Pacific Biosciences of California's convertible debt (non-current) changed year-over-year?
- Pacific Biosciences of California's convertible debt (non-current) decreased by 0.3% year-over-year, from $646.21M to $644.11M.
- What is the long-term trend for Pacific Biosciences of California's convertible debt (non-current)?
- Over 4 years (2021 to 2025), Pacific Biosciences of California's convertible debt (non-current) has grown at a -7.9% compound annual growth rate (CAGR), from $896.07M to $645.38M.
- What does convertible debt (non-current) mean?
- This represents the portion of long-term debt obligations that can be converted into equity shares of the company at the holder's option. It serves as a financing instrument that balances debt service requirements with the potential for future equity dilution. Tracking this metric helps investors evaluate the company's long-term leverage, capital structure, and the potential impact of future share issuance on earnings per share.